Although Not Improving DFS, Adjuvant Avelumab May Potentially Reduce the Risk of Death in Patients with High-Risk TNBC By Ogkologos - September 9, 2025 738 0 Facebook Twitter Google+ Pinterest WhatsApp Findings from the A-BRAVE study Source RELATED ARTICLESMORE FROM AUTHOR Giredestrant plus everolimus prolongs PFS among patients with ER-positive, HER2-negative, ESR1-mutated advanced breast cancer after the receipt of a CDK4/6 inhibitor EMA Recommends Granting a Marketing Authorisation for Ensartinib Taking on the RAS Challenge MOST POPULAR Benefit in OS with Neoadjuvant Pembrolizumab Plus Chemotherapy Followed by Adjuvant... October 4, 2024 Introducing our new podcast for researchers February 4, 2022 Ralph, Medical Dog, Retires From Colorado Children’s Hospital To Focus On... July 29, 2021 T-DM1 is Active and Well Tolerated in Patients with HER2-positive Metastatic... July 9, 2020 Load more HOT NEWS Weak Immunogenicity in Patients with Cancer After First Dose of mRNA-based... Cancer Immunotherapies Don’t Work for Everyone: HLA Gene May Explain Why Substantial Decrease in the Use of Minimally Invasive Surgery for Cervical... Cancer in My Community: Continuing to Improve Australia’s Strong Cancer Survival...
